Anterior gradient-2(AGR2)基因是一种与肿瘤生长、转移、浸润及耐药性密切相关 的基因，以 AGR2 为靶点的人源化单克隆抗体 rhAGR2-mAb 有望成为一种新型的抗肿瘤 药物． 本研究为了进行该抗体的成药性评价，通过瞬时转染的方法分别用 HEK293F 细胞 与 CHO 细胞这两种最常用的表达系统表达 rhAGR2-mAb，获得了纯度为 95% 的抗体蛋 白，同时比较了不同宿主细胞生产的蛋白在分子量、等电点、糖型等方面的差异，发现在分 子量、等电点和糖基化的糖型种类方面，两种宿主细胞表达的 rhAGR2-mAb 并无明显差 异，但两者表达的产物在糖型比例上有较大不同，这也导致了两种表达系统所表达的蛋白 与抗原 AGR2 的亲和力略有不同，为 rhAGR2-mAb 将来选择合适的蛋白瞬时表达系统和 稳定生产系统提供依据．

Anterior gradient-2 (AGR2) gene is expressed in many organs of human body，which is closely related to tumor growth，metastasis，invasion and drug resistance． In this study，we successfully developed a humanized monoclonal antibody，rhAGR2-mAb，which can specifically binds with AGR2 to be a new anti-tumor drug． In or- der to evaluate the activity of this antibody，rhAGR2-mAb was expressed with HEK293F cells and CHO cells by transient transfections and this protein with 95% purity was obtained． Then the properties of rhAGR2-mAb inclu- ding molecular weights，isoelectric points，glycan structures expressed in CHO cells and HEK cells were com- pared． The results show that there are no detected differences between HEK293F cells and CHO cells on molecular weights，isoelectric points，glycosylation types． However，the product of two expressions are found different in glycosylation types proportion，which makes them differ in affinities with AGR2． This provides data for selecting a suitable expression system to transiently and stably express rhAGR2-mAb in the future．